Form 4: Immuneering Corp Executive Leah R. Neufeld's Stock Option Repricing

Leah R. Neufeld, Chief People Officer of Immuneering Corp, had her stock options repriced to $3.01 per share on May 21, 2024, as approved by the Issuer's Board of Directors.

Summary

• On May 21, 2024, Immuneering Corp's Board of Directors approved the repricing of stock options held by Leah R. Neufeld, the Chief People Officer.
• The exercise price for these options was adjusted to $3.01 per share.
• The repricing includes a clause where the exercise price reverts to the original price if Neufeld is terminated for cause, resigns (excluding death or disability), or elects to exercise the options before June 30, 2025, unless there is a change of control of the Issuer.
• Neufeld acquired 88,600 options at $3.01, repriced 88,600 options from $13.85 to $3.01, acquired 105,000 options at $3.01, repriced 105,000 options from $4.25 to $3.01, acquired 60,500 options at $3.01 and repriced 60,500 options from $6.09 to $3.01.
• The options have varying vesting schedules, with some vesting monthly over three or four years.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a change in beneficial ownership due to option repricing. The impact is moderately positive as it incentivizes a key employee, but there are potential negative perceptions related to option dilution.

Positives

• The repricing of options may incentivize Leah R. Neufeld to remain with the company and contribute to its success.
• The repricing could make the options more attractive to Neufeld, potentially aligning her interests with those of the shareholders.

Negatives

• The potential reversion of the exercise price to the original price under certain conditions could be seen as a negative if Neufeld leaves the company under those circumstances before June 30, 2025.
• Repricing of options can sometimes be viewed negatively by shareholders if not properly justified, as it dilutes existing equity value.

Risks

• The condition that could revert the exercise price to the original price introduces uncertainty.
• There is a risk that the repricing may not have the intended effect of incentivizing Neufeld if the stock price does not increase significantly.

Future Outlook

The document does not contain specific forward-looking statements beyond the conditions related to the option repricing.

Management Comments

• The Issuer's Board of Directors approved an option repricing whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share.

Industry Context

Option repricing is a common practice in the biotech industry to retain and incentivize key employees, especially when a company's stock price has underperformed.

Comparison to Industry Standards

• Repricing of stock options is a fairly common practice in the biotechnology industry, particularly for companies like Immuneering Corp that are in the growth phase.
• Companies such as Amgen, Biogen, and Gilead Sciences also use stock options as part of their compensation packages, but repricing events are dependent on specific company performance and market conditions.
• The vesting schedules described are fairly standard, with monthly vesting over three to four years being typical for executive stock options.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the options are exercised.
• Employees may view the repricing positively as it demonstrates the company's commitment to retaining key personnel.
• The repricing could incentivize the Chief People Officer to improve company performance, benefiting all stakeholders.

Key Dates